{"id":"https://openalex.org/W4247934501","doi":"https://doi.org/10.1182/blood.v110.11.1183.1183","title":"Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.","display_name":"Preliminary Results of CNTO 328, an Anti-Interleukin (IL)-6 Monoclonal Antibody (mAb), in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma.","publication_year":2007,"publication_date":"2007-11-16","ids":{"openalex":"https://openalex.org/W4247934501","doi":"https://doi.org/10.1182/blood.v110.11.1183.1183"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v110.11.1183.1183","doi":"https://doi.org/10.1182/blood.v110.11.1183.1183","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.1183.1183","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5077135387","display_name":"Robert Manges","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Robert F. Manges","raw_affiliation_strings":["Investigative Clinical Research of Indiana, L.L.C., Indianapolis, IN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Investigative Clinical Research of Indiana, L.L.C., Indianapolis, IN, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088402798","display_name":"Heather J. Sutherland","orcid":"https://orcid.org/0000-0001-8872-1934","observed_orcids":["https://orcid.org/0000-0001-8872-1934"]},"institutions":[{"id":"https://openalex.org/I2802832906","display_name":"Vancouver General Hospital","ror":"https://ror.org/02zg69r60","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I141074466","https://openalex.org/I2799475292","https://openalex.org/I2802832906"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Heather J. Sutherland","raw_affiliation_strings":["Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology, Vancouver General Hospital, Vancouver, BC, Canada","institution_ids":["https://openalex.org/I2802832906"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028046297","display_name":"Sundar Jagannath","orcid":"https://orcid.org/0000-0003-2934-6518","observed_orcids":["https://orcid.org/0000-0003-2934-6518"]},"institutions":[{"id":"https://openalex.org/I4210091615","display_name":"Saint Vincent's Catholic Medical Center","ror":"https://ror.org/00cwrhn79","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210091615"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sundar Jagannath","raw_affiliation_strings":["Saint Vincent\u2019s Comprehensive Cancer Center, New York, NY, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Saint Vincent\u2019s Comprehensive Cancer Center, New York, NY, USA","institution_ids":["https://openalex.org/I4210091615"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5038235561","display_name":"Robert Zygmunt Orlowski","orcid":"https://orcid.org/0000-0002-5723-4129","observed_orcids":["https://orcid.org/0000-0002-5723-4129"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Z. Orlowski","raw_affiliation_strings":["Lineberger Comprehensive Cancer Center, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lineberger Comprehensive Cancer Center, the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010632198","display_name":"David A. La Police","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"David La Police","raw_affiliation_strings":["Clinical Trials Management, Oncology, Centocor R&D, Inc., Malvern, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Trials Management, Oncology, Centocor R&D, Inc., Malvern, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061685479","display_name":"Mark DeWitte","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark DeWitte","raw_affiliation_strings":["Clinical Hematology & Oncology, Centocor R&D, Inc., Malvern, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Hematology & Oncology, Centocor R&D, Inc., Malvern, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112017868","display_name":"Zhihui Lang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhihui Lang","raw_affiliation_strings":["Clinical Hematology & Oncology, Centocor R&D, Inc., Malvern, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Hematology & Oncology, Centocor R&D, Inc., Malvern, PA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079684551","display_name":"Robert E. Corringham","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert E. Corringham","raw_affiliation_strings":["Clinical Hematology & Oncology, Centocor R&D, Inc., Malvern, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Hematology & Oncology, Centocor R&D, Inc., Malvern, PA, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108371268","display_name":"Jean Fran\u00e7ois Rossi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210093292","display_name":"Centre Hospitalier Universitaire de Montpellier","ror":"https://ror.org/00mthsf17","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210093292"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean Francois Rossi","raw_affiliation_strings":["University Hospital, Montpellier, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University Hospital, Montpellier, France","institution_ids":["https://openalex.org/I4210093292"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5010632198","https://openalex.org/A5077135387"],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.6207,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.74041017,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"110","issue":"11","first_page":"1183","last_page":"1183"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/anti-il-6-monoclonal-antibody","display_name":"anti-IL-6 monoclonal antibody","score":0.8899999856948853},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9480000138282776},{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.8930000066757202},{"id":"https://openalex.org/keywords/il-6-signaling","display_name":"IL-6 signaling","score":0.8059999942779541},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6869999766349792},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.6209999918937683},{"id":"https://openalex.org/keywords/partial-response","display_name":"partial response","score":0.7269999980926514},{"id":"https://openalex.org/keywords/dexamethasone","display_name":"dexamethasone","score":0.7369999885559082},{"id":"https://openalex.org/keywords/maintenance-therapy","display_name":"maintenance therapy","score":0.3659999966621399},{"id":"https://openalex.org/keywords/chimeric-monoclonal-antibody","display_name":"chimeric monoclonal antibody","score":0.6930000185966492},{"id":"https://openalex.org/keywords/proteasome-inhibitor-resistance","display_name":"proteasome inhibitor resistance","score":0.5080000162124634}],"concepts":[{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.940814733505249},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7783594131469727},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7231534719467163},{"id":"https://openalex.org/C2780401358","wikidata":"https://www.wikidata.org/wiki/Q422252","display_name":"Dexamethasone","level":2,"score":0.6975440979003906},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4688390791416168},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42436540126800537},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38492298126220703},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.35983458161354065},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3509669005870819}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v110.11.1183.1183","doi":"https://doi.org/10.1182/blood.v110.11.1183.1183","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v110.11.1183.1183","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2523288082","https://openalex.org/W2993661873","https://openalex.org/W2167757748","https://openalex.org/W2598812192","https://openalex.org/W2242642640","https://openalex.org/W2979319083","https://openalex.org/W2054480018","https://openalex.org/W2009140079","https://openalex.org/W2478354210","https://openalex.org/W2557456859"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Bortezomib":[2],"represents":[3],"a":[4,19,107,143,163,192,243,291],"significant":[5],"advance":[6],"in":[7,52,83,86,98,122,162,263,365,376],"the":[8,27,58,152,182,207,216,267,296,311,377,387],"treatment":[9,148,314,388],"of":[10,21,26,62,106,145,194,209,227,245,304,310,381,389],"relapsed/refractory":[11],"myeloma,":[12],"but":[13],"its":[14,409],"efficacy":[15,375],"is":[16,39,299,401,405],"limited":[17],"by":[18,117,129],"number":[20,303],"resistance":[22],"mechanisms":[23],"including":[24],"activation":[25],"anti-apoptotic":[28],"heat":[29],"shock":[30],"protein":[31],"(HSP)":[32],"and":[33,88,136,179,185,253,321,345,355,374,403],"stress":[34],"response":[35,269],"pathways.":[36],"CNTO":[37,111,343,363],"328":[38,344,364],"an":[40,78,382],"anti-IL-6":[41,362],"chimeric":[42],"monoclonal":[43],"antibody":[44],"shown":[45],"to":[46,80,157,288,318,324,342,407],"have":[47],"anti":[48],"-":[49],"myeloma":[50,91],"activities":[51],"vitro.":[53],"Because":[54],"IL-6":[55,63],"signaling":[56,64],"augments":[57],"HSP":[59],"response,":[60],"downregulation":[61],"may":[65],"enhance":[66],"bortezomib\u2019s":[67],"clinical":[68],"anti-myeloma":[69],"activity.":[70],"Pre-clinical":[71],"studies":[72],"demonstrated":[73],"that":[74],"this":[75,102,399],"combination":[76,123,366,400],"had":[77,281],"additive":[79],"synergistic":[81],"effect":[82],"inducing":[84],"apoptosis":[85],"IL-6-dependent":[87],"independent":[89],"multiple":[90,393],"cell":[92,261],"lines":[93],"(Voorhees":[94],"et":[95],"al.,":[96],"2007,":[97],"press).":[99],"Methods:":[100],"In":[101],"safety":[103,373],"lead-in":[104],"cohort":[105],"pivotal":[108,384],"trial":[109,385],"(clinicaltrials.gov),":[110],"328,":[112],"6":[113,218,379],"mg/kg,":[114],"was":[115,155,170,174,307],"administered":[116,306],"IV":[118,130],"every":[119,138],"2":[120,246],"weeks":[121],"with":[124,361,367,398],"bortezomib,":[125],"1.3":[126],"mg/m2,":[127],"given":[128,180,204],"on":[131,181,206,332],"days":[132],"1,":[133],"4,":[134],"8,":[135],"11":[137],"3":[139],"weeks.":[140],"Pateints":[141],"received":[142],"maximum":[144,193],"four,":[146,158],"6-week":[147],"cycles,":[149],"after":[150,187],"which":[151],"bortezomib":[153,189,210,346,368],"schedule":[154],"reduced":[156],"once":[159],"weekly":[160],"doses":[161],"5-week":[164],"maintenance":[165],"cycle.":[166],"When":[167],"disease":[168,319],"progression":[169,320],"documented,":[171],"oral":[172],"dexamethasone":[173,203],"added":[175],"at":[176],"20":[177,201],"mg":[178,202],"day":[183,186,208],"of,":[184],"each":[188],"infusion,":[190],"for":[191,295,372,386],"two":[195,279],"cycles.":[196],"All":[197],"later":[198],"cycles":[199,305],"included":[200,224],"only":[205],"administration.":[211],"Results:":[212],"Preliminary":[213],"results":[214],"from":[215],"first":[217,378],"patients":[219,272,280,312,330,380],"are":[220],"available.":[221],"Pateint":[222],"characteristics":[223],"median":[225,244,302],"age":[226],"68":[228],"years;":[229],"B2M":[230],">":[231,239],"3.0":[232,240],"mg/L,":[233],"(n":[234],"=":[235],"4":[236,329],"pateints);":[237],"CRP":[238],"mg/L":[241],"(3);":[242],"prior":[247,254,287],"regimens":[248],"(range":[249],"1":[250,316,322],"\u2013":[251],"3),":[252],"bone":[255],"marrow":[256],"or":[257,391],"peripheral":[258],"blood":[259],"stem":[260],"transplantation":[262],"three":[264,271],"patients.":[265],"Using":[266],"EBMT":[268],"criteria,":[270],"achieved":[273],"confirmed":[274],"partial":[275],"responses":[276],"(PRs).":[277],"Additionally,":[278],"unconfirmed":[282],"PRs.":[283],"One":[284],"patient":[285,298],"discontinued":[286],"confirmation,":[289],"while":[290],"follow":[292],"up":[293],"assessment":[294],"other":[297],"pending.":[300],"The":[301,327],"3.":[308],"Two":[309],"ended":[313],"prematurely,":[315],"due":[317,323],"adverse":[325,336],"events.":[326],"remaining":[328],"continue":[331],"study.":[333],"Grade":[334],"3/4":[335],"events":[337],"(AEs)":[338],"considered":[339],"possibly":[340],"related":[341],"include":[347],"neutropenia":[348],"(2":[349],"patients),":[350],"leukopenia":[351],"(1),":[352,354],"lymphopenia":[353],"bloody":[356],"diarrhea":[357],"(1).":[358],"Conclusion:":[359],"Treatment":[360],"has":[369],"been":[370],"evaluated":[371],"ongoing":[383],"relapsed":[390],"refractory":[392],"myeloma.":[394],"Initial":[395],"activity":[396],"observed":[397],"encouraging,":[402],"enrollment":[404],"continuing":[406],"explore":[408],"full":[410],"potential.":[411]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2022-05-12T00:00:00"}